SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong7/29/2025 7:32:20 AM
1 Recommendation

Recommended By
Return to Sender

   of 8239
 
GeneDx beats Q2 estimates, raises FY guidance

Jul. 29, 2025 6:34 AM ET
By: Manshi Mamtora, CFA

  • GeneDx Holdings Corp. press release (NASDAQ: WGS): Q2 GAAP EPS of $0.36 beats by $0.50.
  • Revenue of $102.7M (+45.7% Y/Y) beats by $17.12M.
  • GeneDx Full Year 2025 Guidance

    GeneDx has raised certain elements of its full year 2025 guidance and expects to deliver:

    Metric

    		Previous Guidance

    		Updated Guidance

    Revenue

    		$360 to $375 million

    		$400 to $415 million

    Growth in exome and genome revenue

    		30%

    		48% to 52%

    Growth in exome and genome volume

    		30%

    		30%

    Adjusted gross margin

    		66% to 68%

    		68% to 71%

    Adjusted net income

    		Positive each quarter and for full year

    		Positive each quarter and for full year


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News